ICER report questions cost-effectiveness of PARP inhibitors in ovarian cancer

31 August 2017

The Institute for Clinical and Economic Review (ICER), a Boston, USA-based health economic research group, has released a report assessing the comparative clinical effectiveness and value of three PARP inhibitors in ovarian cancer.

The report compares AstraZeneca’s (LSE: AZN) Lynparza (olaparib), Tesaro’s (Nasdaq: TSRO) Zejula (niraparib) and Clovis Oncology’s (Nasdaq: CLVS) Rubraca (rucaparib).

The ICER says that, for patients with recurrent, BRCA-mutated disease, the net health benefit of both Lynparza and Rubraca was “promising but inconclusive,” citing the fact that there are no comparative studies looking at alternatives.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK